SCYX SCYNEXIS, Inc.

1.63
-0.06  -4%
Previous Close 1.69
Open 1.70
Price To book 1.29
Market Cap 42.05M
Shares 25,798,000
Volume 211,773
Short Ratio 7.57
Av. Daily Volume 470,478

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Clinical hold placed on the initiation of intravenous (IV) SCY-078 until the FDA completes a review of all data. Clinical hold follows three mild-to-moderate thrombotic events in healthy volunteers - announced March 2, 2017. Noted May 8, 2017 that Phase 2 trial to be initiated in 2018.
Intravenous SCY-078
Phase 2 data released June 2016. Full study results released October 2016.
SCY-078
Vulvovaginal candidiasis (VVC)
Phase 3 open label trial to commence 2Q 2017.
SCY-078 - oral (FURI)
Invasive candidiasis

Latest News

  1. Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS’ Lead Agent to Combat Serious and Life-threatening Fungal Infections
  2. ETFs with exposure to SCYNEXIS, Inc. : May 15, 2017
  3. SCYNEXIS, Inc. :SCYX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  4. Potent in vitro Activity of SCYNEXIS’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention (CDC)
  5. Scynexis reports 1Q loss
  6. SCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status
  7. SHAREHOLDER ANNOUNCEMENT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017
  8. DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
  9. DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 - SCYX
  10. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against SCYNEXIS, Inc. (SCYX) & Lead Plaintiff Deadline - May 8, 2017
  11. MAY 8 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
  12. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in SCYNEXIS, Inc. of Class Action Lawsuit and Upcoming Deadline - SCYX
  13. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In SCYNEXIS, Inc. To Contact The Firm Before Lead Plaintiff Deadline
  14. DEADLINE MONDAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017
  15. MONDAY DEADLINE: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
  16. EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of SCYNEXIS, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017 - SCYX
  17. 5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
  18. DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In SCYNEXIS, Inc. (Nasdaq: SCYX) To Contact The Firm
  19. DEADLINE ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against SCYNEXIS, Inc. and Reminds Investors with Losses to Contact the Firm
  20. SCYX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving SCYNEXIS, Inc. and a Lead Plaintiff Deadline of May 8, 2017